http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004161751-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-5304 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-60 |
| filingDate | 2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c98e0d8fcdff29dad320b9f814be9249 |
| publicationDate | 2004-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2004161751-A1 |
| titleOfInvention | Compositons for trp-m8 binding and radioreceptor methods therewith |
| abstract | One embodiment of the invention is a composition that comprises a radioactive 32 P or 33 P phosphine oxide molecule. The said composition is designed to bind to the transient potential receptor-M8 (TRP-M8) receptor of cells. The radioactive 32 P or 33 P phosphine oxide ligand may be used for radioreceptor binding studies and for diagnostic studies of cancerous tissues. The TRP-M8 receptor is selectively expressed in malignant tissues such as prostate cancer cells. Affinity of the 32 P or 33 P phosphine oxide ligand for the TRP-M8 receptor confers selectivity and specificity in delivering lethal radiation to the diseased cells. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7893072-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016535742-A |
| priorityDate | 2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.